BRCA2‐positive lung adenocarcinoma treated with olaparib: A case report

• DOI: 10.1002/rcr2.1317
• Publication Date: 2024-03-07T10:52:11Z
• Authors: Takumi Motohashi; Kazutoshi Isobe; Takahiro Yoshizawa; Yusuke Usui; Hiroshige Shimizu; Muneyuki Sekiya; Shion Miyoshi; Yasuhiko Nakamura; Naohisa Urabe; Susumu Sakamoto; Sakae Homma; Sota Sadamoto; Naobumi Tochigi; Kazuma Kishi
• Keywords: Diseases of the respiratory system; adenocarcinoma; BRCA2 gene mutation; RC705-779; cancer genomic profiling test; Case Reports; olaparib

AbstractA 66‐year‐old woman was found to have abnormal shadows on a chest radiograph at a previous hospital 4 years ago, which led to a diagnosis of lung adenocarcinoma, cT2aN1M1b stage IVA. First‐line treatment included carboplatin and paclitaxel plus thoracic radiotherapy and stereotactic radiation therapy for brain metastases. The patient later underwent second‐line pemetrexed treatment, followed by third‐line nivolumab, fourth‐line docetaxel and bevacizumab, fifth‐line tegafur‐gimeracil‐oteracil, and sixth‐line gemcitabine. Two years ago, after observing an increase in the primary lesion and carcinoembryonic antigen levels (104.0 ng/mL), a computed tomography‐guided biopsy was performed from the primary site of lung cancer. A cancer genomic profiling test (FoundationOne® CDx cancer genome profile) revealed a breast cancer susceptibility (BRCA) 2 gene mutation. Therefore, she started taking olaparib. The treatment led to stable disease for approximately 2 years.